Avoid common mistakes on your manuscript.
Correction to: Current Hematologic Malignancy Reports
The original online version of this article was revised to update the following statement (changes are in bold font):
FROM:
"In another randomized placebo-controlled trial, 130 patients with hemoglobin less than 10 g/dL were randomized in a 2:1 fashion to receive darbepoetin 450 IU/kg/week or placebo. Erythroid response based on the International Working Group (IWG) 2006 criteria was 45.9% in the darbepoetin arm compared to 4.4% for placebo (p < 0.0001) [36]."
Replace with:
"In another randomized placebo-controlled trial, 130 patients with hemoglobin less than 10 g/dL were randomized in a 2:1 fashion to receive epoetin-alfa 450 IU/kg/week or placebo. Erythroid response based on the International Working Group (IWG) 2006 criteria was 45.9% in the epoetin arm compared to 4.4% for placebo (p < 0.0001) [34]."
FROM:
"The findings revealed significant advantages associated with luspatercept treatment: approximately 38% of patients treated with luspatercept achieved transfusion independence, a notably higher rate than the 13% observed in the epoetin alfa group. Furthermore, luspatercept demonstrated a substantial reduction in the median red blood cell transfusion burden by 44%, whereas the epoetin alfa group showed a reduction of 13%, underscoring the superior efficacy of luspatercept in reducing transfusion requirements."
Replace with:
"The findings revealed significant advantages associated with luspatercept treatment: approximately 59% of patients treated with luspatercept achieved the primary endpoint of transfusion independence and a concurrent mean hemoglobin increase of at least 1.5 g/dL, a notably higher rate than the 31% observed in the epoetin alfa group."
The statement "Furthermore, luspatercept demonstrated a substantial reduction in the median red blood cell transfusion burden by 44%, whereas the epoetin alfa group showed a reduction of 13%, underscoring the superior efficacy of luspatercept in reducing transfusion requirements." was removed.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kewan, T., Stahl, M., Bewersdorf, J.P. et al. Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities. Curr Hematol Malig Rep 19, 151 (2024). https://doi.org/10.1007/s11899-024-00734-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11899-024-00734-x